Eisai, GE reach R&D deal for Alzheimer's

04/28/2013 | DOTMed.com · AuntMinnie.com (free registration)

GE Healthcare has announced a collaboration with Eisai focused on research and development of treatments for Alzheimer's disease. GE said its candidate PET agent flutemetamol will be used by Eisai in choosing patients for an early-stage study of Eisai's beta-site amyloid precursor protein-cleaving enzyme inhibitor E2609 as a possible treatment for the disease.

View Full Article in:

DOTMed.com · AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ